Valery Z. Grdzelishvili

Dr. Valery Z. Grdzelishvili


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
DKDavid B. Kushner
David B. Kushner
BLBrett D. Lindenbach
Brett D. Lindenbach
Valery GrdzelishviliValery Grdzelishvili
Valery Grdzelishvili
ANAmine O. Noueiry
Amine O. Noueiry
SPScott M. Paul
Scott M. Paul
PAPaul Ahlquist
Paul Ahlquist
Positive-strand RNA viruses are the largest virus class and include many pathogens such as hepatitis C virus and the severe acute respiratory syndrome coronavirus (SARS). Brome mosaic virus (BMV) is a representative positive-strand RNA virus whose RNA replication, gene expression, and encapsidation have been reproduced in the yeast Saccharomyces cerevisiae . By using traditional yeast genetics, host genes have been identified that function in controlling BMV translation, selecting BMV RNAs as replication templates, activating the replication complex, maintaining a lipid composition required for membrane-associated RNA replication, and other steps. To more globally and systematically identify such host factors, we used engineered BMV derivatives to assay viral RNA replication in each strain of an ordered, genome-wide set of yeast single-gene deletion mutants. Each deletion strain was transformed to express BMV replicase proteins and a BMV RNA replication template with the capsid gene replaced by a luciferase reporter. Luciferase expression, which is dependent on viral RNA replication and RNA-dependent mRNA synthesis, was measured in intact yeast cells. Approximately 4,500 yeast deletion strains (≈80% of yeast genes) were screened in duplicate and selected strains analyzed further. This functional genomics approach revealed nearly 100 genes whose absence inhibited or stimulated BMV RNA replication and/or gene expression by 3- to >25-fold. Several of these genes were shown previously to function in BMV replication, validating the approach. Newly identified genes include some in RNA, protein, or membrane modification pathways and genes of unknown function. The results further illuminate virus and cell pathways. Further refinement of virus screening likely will reveal contributions from additional host genes.

1 December 2012 in Journal of General Virology
Verified
Journal Article
Open access
EHEric Hastie
Eric Hastie
Valery GrdzelishviliValery Grdzelishvili
Valery Grdzelishvili
Oncolytic virus (OV) therapy is an emerging anti-cancer approach that utilizes viruses to preferentially infect and kill cancer cells, while not harming healthy cells. Vesicular stomatitis virus (VSV) is a prototypic non-segmented, negative-strand RNA virus with inherent OV qualities. Antiviral responses induced by type I interferon pathways are believed to be impaired in most cancer cells, making them more susceptible to VSV than normal cells. Several other factors make VSV a promising OV candidate for clinical use, including its well-studied biology, a small, easily manipulated genome, relative independence of a receptor or cell cycle, cytoplasmic replication without risk of host-cell transformation, and lack of pre-existing immunity in humans. Moreover, various VSV-based recombinant viruses have been engineered via reverse genetics to improve oncoselectivity, safety, oncotoxicity and stimulation of tumour-specific immunity. Alternative delivery methods are also being studied to minimize premature immune clearance of VSV. OV treatment as a monotherapy is being explored, although many studies have employed VSV in combination with radiotherapy, chemotherapy or other OVs. Preclinical studies with various cancers have demonstrated that VSV is a promising OV; as a result, a human clinical trial using VSV is currently in progress.

1 September 2013 in Virus Research
Verified
Journal Article
Closed access
EHEric Hastie
Eric Hastie
MCMarcela Cataldi
Marcela Cataldi
IMIan Marriott
Ian Marriott
Valery GrdzelishviliValery Grdzelishvili
Valery Grdzelishvili

1 February 2013 in Virology
Verified
Journal Article
Closed access
MMMegan Moerdyk-Schauwecker
Megan Moerdyk-Schauwecker
NSNirav R. Shah
Nirav R. Shah
AMAndrea M. Murphy
Andrea M. Murphy
EHEric Hastie
Eric Hastie
PMPinku Mukherjee
Pinku Mukherjee
Valery GrdzelishviliValery Grdzelishvili
Valery Grdzelishvili

1 December 2017 in Journal of General Virology
Verified
Journal Article
Open access
SFSébastien A. Felt
Sébastien A. Felt
Valery GrdzelishviliValery Grdzelishvili
Valery Grdzelishvili
Oncolytic virus (OV) therapy is an anti-cancer approach that uses viruses that preferentially infect, replicate in and kill cancer cells. Vesicular stomatitis virus (VSV, a rhabdovirus) is an OV that is currently being tested in the USA in several phase I clinical trials against different malignancies. Several factors make VSV a promising OV: lack of pre-existing human immunity against VSV, a small and easy to manipulate genome, cytoplasmic replication without risk of host cell transformation, independence of cell cycle and rapid growth to high titres in a broad range of cell lines facilitating large-scale virus production. While significant advances have been made in VSV-based OV therapy, room for improvement remains. Here we review recent studies (published in the last 5 years) that address ‘old’ and ‘new’ challenges of VSV-based OV therapy. These studies focused on improving VSV safety, oncoselectivity and oncotoxicity; breaking resistance of some cancers to VSV; preventing premature clearance of VSV; and stimulating tumour-specific immunity. Many of these approaches were based on combining VSV with other therapeutics. This review also discusses another rhabdovirus closely related to VSV, Maraba virus, which is currently being tested in Canada in phase I/II clinical trials.

15 June 2005 in Journal of Virology
Verified
Journal Article
Open access
PDF file
Valery GrdzelishviliValery Grdzelishvili
Valery Grdzelishvili
SSSherin Smallwood
Sherin Smallwood
DTDallas Tower
Dallas Tower
RHRichard L. Hall
Richard L. Hall
DHD. Margaret Hunt
D. Margaret Hunt
SMSue A. Moyer
Sue A. Moyer
The vesicular stomatitis virus (VSV) RNA polymerase synthesizes viral mRNAs with 5′-cap structures methylated at the guanine- N 7 and 2′- O -adenosine positions (7mGpppA m ). Previously, our laboratory showed that a VSV host range ( hr ) and temperature-sensitive ( ts ) mutant, hr1 , had a complete defect in mRNA cap methylation and that the wild-type L protein could complement the hr1 defect in vitro. Here, we sequenced the L, P, and N genes of mutant hr1 and found only two amino acid substitutions, both residing in the L-polymerase protein, which differentiate hr1 from its wild-type parent. These mutations (N505D and D1671V) were introduced separately and together into the L gene, and their effects on VSV in vitro transcription and in vivo chloramphenicol acetyltransferase minigenome replication were studied under conditions that are permissive and nonpermissive for hr1 . Neither L mutation significantly affected viral RNA synthesis at 34°C in permissive (BHK) and nonpermissive (HEp-2) cells, but D1671V reduced in vitro transcription and genome replication by about 50% at 40°C in both cell lines. Recombinant VSV bearing each mutation were isolated, and the hr and ts phenotypes in infected cells were the result of a single D1671V substitution in the L protein. While the mutations did not significantly affect mRNA synthesis by purified viruses, 5′-cap analyses of product mRNAs clearly demonstrated that the D1671V mutation abrogated all methyltransferase activity. Sequence analysis suggests that an aspartic acid at amino acid 1671 is a critical residue within a putative conserved S -adenosyl- l -methionine-binding domain of the L protein.